Biocon Plans to Introduce New Psoriasis Drug in July-Sept Quarter

January 25, 2013 7:04 AM GMT

  • FOLLOW IBT: YOUR ONE-STOP NEWS SITE
  • Google Plus
(Photo: Reuters/Jagadeesh Nv/Files)<br>Kiran Mazumdar-Shaw, chairman and managing director of Biocon Ltd., speaks during a news conference in Bangalore March 8, 2007.
(Photo: Reuters/Jagadeesh Nv/Files)
Kiran Mazumdar-Shaw, chairman and managing director of Biocon Ltd., speaks during a news conference in Bangalore March 8, 2007.

Biocon(BION.NS), India's top listed biotech firm, plans to launch psoriasis drug Alzumab in the country in the July-September quarter, a top company executive said on Friday.

Share article

The company expects sales of 1 billion rupees from the drug over four years, Kiran Mazumdar-Shaw, chairman, Biocon said in a conference call.

Late on Thursday, Biocon reported an 8.24 percent rise in net profit to 920 million rupees for the Oct-Dec quarter compared with a year earlier.

Copyright 2012 Thomson Reuters. All rights reserved.
Join the Conversation
Universal Credit: UK benefits shake-up begins